Table 1 Clinicopathological features of metaplastic breast carcinoma, invasive ductal carcinoma and triple-negative invasive ductal carcinoma
Metaplastic breast cancer (N = 55) | Invasive ductal carcinoma (N = 767) | TN-IDC (N = 131) | |||
|---|---|---|---|---|---|
Features | N (%) | N (%) | P | N (%) | P |
Age | 0.594 | 0.264 | |||
≤50 | 27 (49.09) | 405 (52.80) | 76 (58.02) | ||
>50 | 28 (50.91) | 362 (47.20) | 55 (41.98) | ||
Stage | 0.001 | <0.001 | |||
I | 4 (7.27) | 107 (13.95) | 21 (16.03) | ||
II | 30 (54.55) | 522 (68.06) | 92 (70.23) | ||
III | 16 (29.09) | 87 (11.34) | 8 (6.11) | ||
Unknown | 5 (9.09) | 51 (6.65) | 10 (7.63) | ||
Operation | 0.051 | 0.054 | |||
Breast-conserving surgery | 4 (7.27) | 134 (17.47) | 25 (19.08) | ||
Modified radical mastectomy | 51 (92.73) | 633 (82.53) | 106 (80.92) | ||
Chemotherapy | 0.302 | 0.295 | |||
Yes | 48 (87.28) | 627 (81.74) | 106 (80.91) | ||
No | 7 (12.73) | 140 (18.25) | 25 (19.08) | ||
Radiotherapy | <0.001 | <0.001 | |||
Yes | 27 (49.09) | 177 (23.08) | 29 (22.14) | ||
No | 28 (50.91) | 590 (76.92) | 102 (77.86) | ||
Hormone therapy | <0.001 | ||||
Yes | 13 (23.64) | 522 (68.06) | — | ||
No | 42 (76.46) | 245 (31.94) | — | ||
Pathological tumor stage | <0.001 | <0.001 | |||
T1 (≤2 cm) | 5 (9.09) | 317 (41.33) | 58 (44.27) | ||
T2 (2–5 cm) | 22 (40.00) | 332 (43.29) | 55 (41.98) | ||
T3 (>5 cm) | 22 (40.00) | 39 (5.08) | 5 (3.82) | ||
Tx | 6 (10.91) | 79 (10.30) | 13 (9.92) | ||
Pathological nodal stage | 0.001 | 0.001 | |||
N0 | 35 (63.64) | 314 (41.20) | 50 (38.17) | ||
N1-3 | 15 (27.27) | 385 (49.93) | 69 (52.67) | ||
Nx | 5 (9.09) | 68 (8.87) | 12 (9.16) | ||
Histological grade | 0.167 | 0.285 | |||
I or II | 29 (52.73) | 461 (60.10) | 77 (58.78) | ||
III | 20 (36.36) | 227 (29.60) | 41 (31.30) | ||
Unknown | 6 (10.91) | 79 (10.30) | 13 (9.92) | ||
Ki-67 a | <0.001 | <0.001 | |||
≥14% | 47 (87.27) | 486 (63.36) | 80 (61.07) | ||
<14% | 8 (12.73) | 281 (36.64) | 51 (38.93) | ||
P53 b | 0.001 | 0.008 | |||
≥25% | 28 (50.91) | 221 (28.81) | 40 (30.53) | ||
<25% | 27 (49.09) | 546 (71.19) | 91 (69.47) | ||
Estrogen receptor | <0.001 | ||||
+ | 8 (14.55) | 419 (54.63) | — | ||
− | 47 (85.45) | 348 (45.37) | — | ||
Progesterone receptor | <0.001 | ||||
+ | 10 (18.18) | 492 (64.14) | — | ||
− | 45 (81.82) | 276 (35.98) | — | ||
Human epidermal growth factor receptor-2 | 0.005 | ||||
+ | 9 (16.36) | 268 (34.94) | — | ||
− | 46 (83.64) | 499 (65.06) | — | ||
TN-MBC | 37 (67.27) | 131 (18.22) | <0.001 | — | |
Not TN-MBC | 18 (32.73) | 636 (81.78) | — | ||